Real-World Studies
Frontline BTKi Linked to Improved Response and PFS in Primary CNS Lymphoma
Wang et alBlood Advances

High-dose methotrexate-based immunochemotherapy remains the standard frontline treatment for primary CNS lymphoma (PCNSL), but outcomes remain suboptimal with high relapse rates. Although Bruton tyrosine kinase inhibitors (BTKi) demonstrate efficacy in clinical trials, real-world comparative data against conventional induction regimens have been limited.
In a retrospective study evaluating 131 newly diagnosed PCNSL patients, outcomes were evaluated between frontline BTKi-based induction (n=85) and conventional regimens (n=46). Investigators utilized multiple imputation (m=50) and inverse probability of treatment weighting (IPTW) to balance baseline covariates across groups.
In the primary pooled multiple-imputation IPTW analysis, BTKi-based induction was associated with a higher complete response rate (OR 5.50, 95% CI 2.25–13.47; P<0.001) and objective response rate (OR 2.59, 95% CI 1.05–6.36; P=0.038). Frontline BTKi therapy was also associated with improved progression-free survival (HR 0.57, 95% CI 0.32–1.00; P=0.048). The difference in overall survival was not statistically significant (HR 0.65, 95% CI 0.31–1.38; P=0.263), potentially reflecting multifactorial confounding inherent to retrospective analyses. The findings suggest that incorporating BTKi into frontline regimens is associated with favorable response and PFS profiles in newly diagnosed PCNSL, though definitive conclusions regarding overall survival cannot be drawn.
Key Takeaways
- Frontline BTKi-based therapy was associated with a significantly higher complete response rate (OR 5.50, 95% CI 2.25–13.47; P<0.001) and objective response rate (OR 2.59, 95% CI 1.05–6.36; P=0.038) compared with conventional induction regimens.
- BTKi-based regimens were associated with improved progression-free survival (HR 0.57, 95% CI 0.32–1.00; P=0.048), though the difference in overall survival was not statistically significant (HR 0.65, 95% CI 0.31–1.38; P=0.263).
Read the original sourceBlood Advances
